Stoke Therapeutics (STOK)
NASDAQ:STOK
Want to see STOK full AI Analyst Report?
Total Valuation
Stoke Therapeutics has a market cap or net worth of $1.85B. The enterprise value is $1.68B.
Market Cap$1.85B
Enterprise Value$1.68B
Share Statistics
Stoke Therapeutics has 62,281,654 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,281,654
Owned by Insiders34.67%
Owned by Institutions16.22%
Financial Efficiency
Stoke Therapeutics’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.71%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)-5.71%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee1.44M
Profits Per Employee-53.79K
Employee Count128
Asset Turnover0.44
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Stoke Therapeutics is ―. Stoke Therapeutics’s PEG ratio is 2.94.
PE Ratio―
PS Ratio10.19
PB Ratio5.33
Price to Fair Value5.33
Price to FCF41.85
Price to Operating Cash Flow-12.60
PEG Ratio2.94
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 184.42M and earned -6.88M in profits. Earnings per share was -0.12.
Revenue184.42M
Gross Profit184.42M
Operating Income-20.59M
Pretax Income-6.88M
Net Income-6.88M
EBITDA-18.82M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was -146.82M and capital expenditures -871.00K, giving a free cash flow of -147.69M billion.
Operating Cash Flow-146.82M
Free Cash Flow-147.69M
Free Cash Flow per Share-2.37
Dividends & Yields
Stoke Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change213.46%
50-Day Moving Average33.15
200-Day Moving Average29.63
Relative Strength Index (RSI)33.83
Average Volume (3m)538.06K
Important Dates
Stoke Therapeutics upcoming earnings date is Aug 10, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Stoke Therapeutics as a current ratio of 5.28, with Debt / Equity ratio of 0.87%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap0.00
Net Debt to EBITDA4.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Stoke Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Stoke Therapeutics EV to EBITDA ratio is -95.40, with an EV/FCF ratio of 39.97.
EV to Sales9.74
EV to EBITDA-95.40
EV to Free Cash Flow39.97
EV to Operating Cash Flow39.39
Balance Sheet
Stoke Therapeutics has $343.55M in cash and marketable securities with $3.42M in debt, giving a net cash position of $340.12M billion.
Cash & Marketable Securities$343.55M
Total Debt$3.42M
Net Cash$340.12M
Net Cash Per Share$5.46
Tangible Book Value Per Share$5.95
Margins
Gross margin is 90.36%, with operating margin of -11.16%, and net profit margin of -3.73%.
Gross Margin90.36%
Operating Margin-11.16%
Pretax Margin-3.73%
Net Profit Margin-3.73%
EBITDA Margin-10.20%
EBIT Margin-11.16%
Analyst Forecast
The average price target for Stoke Therapeutics is $46.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$46.71
Price Target Upside25.34% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-83.20%
EPS Growth Forecast-439.48%